Atlas Trials

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

Clinical trial NCT05188469 · COMPLETED

Trial details

NCT number
NCT05188469
Sponsor
EyeGene Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
COVID-19 Vaccine
Start date
2022-03-22
Primary completion
2024-05-29
Enrollment
67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.